Get the Stockscreener App
54.69
4.21%
2.21
After Hours:
54.00
-0.69
-1.26%
Biomarin Pharmaceutical Inc stock is traded at $54.69, with a volume of 3.00M.
It is up +4.21% in the last 24 hours and up +1.64% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$52.48
Open:
$52.72
24h Volume:
3.00M
Relative Volume:
1.32
Market Cap:
$10.51B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
20.33
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-0.07%
1M Performance:
+1.64%
6M Performance:
-6.48%
1Y Performance:
-13.81%
1-Day Range:
$52.51
$54.76
1-Week Range:
$51.99
$55.24
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.69 | 10.08B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Finviz
Will BioMarin Pharmaceutical Inc. (BM8) stock beat revenue estimatesWeekly Trend Summary & Comprehensive Market Scan Insights - newser.com
How BioMarin Pharmaceutical Inc. (BM8) stock responds to bond marketTrade Exit Report & Weekly High Conviction Trade Ideas - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock outperform global peersMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Will BioMarin Pharmaceutical Inc. (BM8) stock attract long term capital inflowsJuly 2025 Technicals & Verified Momentum Stock Watchlist - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap vs fundamentalsCEO Change & AI Enhanced Market Trend Forecasts - newser.com
How higher bond yields impact BioMarin Pharmaceutical Inc. (BM8) stock2025 Fundamental Recap & Fast Gain Swing Trade Alerts - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecasts2025 Key Lessons & Fast Gain Stock Tips - newser.com
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Will BioMarin Pharmaceutical Inc. stock split attract more investors - newser.com
Key resistance and support levels for BioMarin Pharmaceutical Inc.CEO Change & Consistent Profit Trade Alerts - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for BioMarin Pharmaceutical Inc. stock2025 Price Action Summary & Weekly Stock Performance Updates - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Risk Controlled Swing Alerts - newser.com
How currency fluctuations impact BioMarin Pharmaceutical Inc. stockJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):